Close Menu

NEW YORK – Singapore-based pharmaceutical company Avatamed has partnered with South Korean biotech Macrogen to commercialize a precision oncology service offering that combines Avatamed's drug screening technology and Macrogen's genomic analysis expertise.

Avatamed's platform identifies cancer drugs patients are likely to respond to by screening the treatments first on their cancer cells, after taking into account the genomic features of those cells. Macrogen evaluates patients' tumor biopsy samples for genomic markers that may be similarly informative for therapy selection.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.